Agios Pharmaceuticals Inc. (AGIO) and Realm Therapeutics Plc (NASDAQ:RLM) Comparison side by side

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) and Realm Therapeutics Plc (NASDAQ:RLM), both competing one another are Biotechnology companies. We will compare their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Agios Pharmaceuticals Inc. 74.17M 42.42 342.52M -6.26 0.00
Realm Therapeutics Plc N/A 0.00 N/A 0.00 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 has Agios Pharmaceuticals Inc. and Realm Therapeutics Plc’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Agios Pharmaceuticals Inc. -461.80% -48.5% -38.3%
Realm Therapeutics Plc 0.00% 0% 0%

Analyst Recommendations

The table shown features the ratings and recommendations for Agios Pharmaceuticals Inc. and Realm Therapeutics Plc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Agios Pharmaceuticals Inc. 0 1 0 2.00
Realm Therapeutics Plc 0 0 0 0.00

The upside potential is 47.93% for Agios Pharmaceuticals Inc. with average price target of $80.

Institutional and Insider Ownership

Agios Pharmaceuticals Inc. and Realm Therapeutics Plc has shares held by institutional investors as follows: 98.3% and 0%. Agios Pharmaceuticals Inc.’s share held by insiders are 0.3%.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Agios Pharmaceuticals Inc. -19.88% -27.56% -29.17% -43.23% -13.33% -7.78%
Realm Therapeutics Plc -32.55% -28.21% 0% 0% 0% -70.18%

For the past year Agios Pharmaceuticals Inc. has stronger performance than Realm Therapeutics Plc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc is based in London, the United Kingdom.